Abstract
We show that TAP/Sec14L2 had a high expression in normal/benign breast, prostate, and liver tissues as compared to lung, colon, and kidney. Its expression was downregulated in breast cancer cell lines shown by quantitative-PCR. Further, 57% of 141 human invasive breast carcinomas had no or markedly reduced TAP/Sec14L2 expression by immunohistochemical staining, and the rate increased to 80% in high grade invasive carcinomas (p < .01). This downregulation of TAP/Sec14L2 was also present in ductal carcinoma in situ (DCIS) associated with invasive carcinomas. These findings raise the possibility that TAP/Sec14L2 may serve as a tumor suppressor in breast carcinogenesis.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibody Specificity
-
Breast Neoplasms / genetics
-
Breast Neoplasms / metabolism*
-
Breast Neoplasms / secondary
-
Carcinoma / genetics
-
Carcinoma / metabolism*
-
Carcinoma / secondary
-
Carcinoma, Intraductal, Noninfiltrating / genetics
-
Carcinoma, Intraductal, Noninfiltrating / metabolism*
-
Carcinoma, Intraductal, Noninfiltrating / secondary
-
Carrier Proteins / genetics
-
Carrier Proteins / metabolism*
-
Cell Line, Tumor
-
Down-Regulation
-
Female
-
Gene Expression Regulation, Neoplastic
-
Humans
-
Immunohistochemistry
-
Lipoproteins / genetics
-
Lipoproteins / metabolism*
-
Lymphatic Metastasis
-
Middle Aged
-
Neoplasm Invasiveness
-
RNA, Messenger / metabolism
-
Reverse Transcriptase Polymerase Chain Reaction
-
Tissue Array Analysis
-
Trans-Activators / genetics
-
Trans-Activators / metabolism*
-
Tumor Suppressor Proteins / genetics
-
Tumor Suppressor Proteins / metabolism*
Substances
-
Carrier Proteins
-
Lipoproteins
-
RNA, Messenger
-
SEC14L2 protein, human
-
Trans-Activators
-
Tumor Suppressor Proteins